Press
Releases
Press Releases
AVROBIO Appoints Dr. Gail Farfel to its Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 21, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel , Ph.D., to its Board of Directors. Dr.
Oct 21, 2020
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2020-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to
Oct 06, 2020
AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
Investigational gene therapy licensed from The University of Manchester, UK aims to address both physical and CNS manifestations of Hunter syndrome Expands leading pipeline targeting lysosomal disorders with 5 th investigational gene therapy Program expected to enter Phase 1/2 clinical trial in the
Oct 05, 2020
AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the
Sep 28, 2020
AVROBIO to Present at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming
Sep 25, 2020
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 4, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to 63,000
Sep 04, 2020
AVROBIO to Present at Three Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2020-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in three upcoming
Sep 03, 2020
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2020-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an
Aug 07, 2020
AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update
New data indicate stable kidney function across the two Fabry disease clinical studies up to 32 months New six-month Phase 2 FAB-201 data from first patient treated using AVROBIO’s plato ® gene therapy platform show continued reduction in toxic metabolite plasma lyso-Gb3 and increased leukocyte and
Aug 06, 2020
AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2020-- AVROBIO, Inc . (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the 2020 Wedbush PacGrow
Aug 05, 2020
Displaying 1 - 10 of 36